SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
TRANSGENOMIC, INC.
(Name of Issuer)
Common Stock, $.01 Par Value
(Title of Class of Securities)
89365K206
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ]. (A
fee is not required only if the filing person: (1) has a previous statement
on the file reporting beneficial ownership of more than five percent of the
class of securities described in Item 1; and (2) has no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such
class.) (See Rule 13d-7.)
*The remainder of this cover page shall be filled our for a reporting
person's initial filing of this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
(Continued on following page(s))
CUSIP NO. 89365K206 13G
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GlaxoSmithKline plc
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
5 SOLE VOTING POWER
NUMBER OF 1,247,687
SHARES
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY
EACH
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 1,247,687
WITH
8 SHARED DISPOSITIVE POWER
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,247,687
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.4%
12 TYPE OF REPORTING PERSON*
CO
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP NO. 89365K206 13G
Item 1. (a). Name of Issuer:
Transgenomic, Inc.
(b). Address of Issuer's Principal Executive Offices:
12325 Emmet Street
Omaha, NE 68164
Item 2. (a). Names of Person Filing:
GlaxoSmithKline plc
(b). Address of Principal Business Office:
980 Great West Road
Brentford
Middlesex
TW8 9GS ENGLAND
(c). Citizenship:
England and Wales
(d). Title of Class of Securities:
Common stock.
(e). CUSIP Number:
89365K206
Item 3. Not Applicable.
Item 4. Ownership.
The information in items 1 and 5 through 11 on the cover pages (page
2) on Schedule 13G is hereby incorporated by reference.
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check
the following [ ].
Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
The following companies are indirect, wholly-owned subsidiaries of
Reporting Person and owners of record for 1,247,687 shares,
collectively:
Owner of Record No. of Shares
S.R.One, Limited (US) 1,108,133
S.R. One Limited (UK) 118,210
S.R. One International B.V. (NETH) 21,344
Of these shares, 165,621; 17,731; and 3,202 shares are held
respectively by S.R. One, Limited (US); S.R.One Limited (UK) and
S.R. One International B.V. (NETH) in an escrow account established
in conjunction with the acquisition of Annovis, Inc. by the Issuer.
Except to the extent that post-closing claims of the Issuer are
satisfied by delivery of shares from the escrow account, the shares
will be held in escrow until May 29, 2002.
Item 7. Identification and Classification of Subsidiaries Which Acquired
the Security Being Reported on by the Parent Holding Company:
Not applicable.
Item 8. Identification and Classification of Members of the Group:
Not applicable.
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certification:
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are not
held for the purpose of or with the effect of changing or
influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any
transaction having such purpose or effect.
Signature:
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
GLAXOSMITHKLINE PLC
By: /s/
--------------------------------------
S.M. Bicknell
Company Secretary
Dated: February 6, 2002